Phase 2 N=16 Treatment of Liver Metastases With Electrochemotherapy
Liver Metastases
Primary: Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms) — 0; 0; 0 events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=49 Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer
Colorectal Cancer · Metastatic Cancer
Primary: 2 Year Disease-free Survival . — 9 percentage of participants
Phase 2 N=23 Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II
Liver Metastases
Primary: Evaluation of Safety Related to Electrochemotherapy — 20; 3; 0; 0 Participants
N/A N=530 FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Colorectal Cancer · Colorectal Carcinoma · Liver Metastases
Primary: Progression-Free Survival (PFS) at Any Site — 10.7; 10.2 Months — p=0.551
Phase 3 N=209 FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Overall Survival (OS) — 25.9; 25.0 months — p=0.43
Phase 2 N=58 Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Colorectal Cancer With Non Resectable Hepatic Metastasis
Primary: Progression-free Survival Rate at 9 Months — 30; 26 Participants
Phase 2 N=70 Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
Colon Cancer With Metastases to the Liver
Primary: Tumor Response — 31; 16 participants
Phase 2 N=14 Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
Colorectal Cancer
Primary: Success of DEBIRI-M1 Procedure as a Measure of Feasibility (Percentage of Successful Treatments) — 100 percentage of successful treatments
Phase 4 N=50 A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
Colorectal Cancer
Primary: Percentage of Participants Achieving Complete Resection (R0 Resection) — 30.0 percentage of participants
Phase 2 N=16 Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
Liver Metastases · Recurrent Colon Cancer · Recurrent Rectal Cancer
Primary: Number of Participants With at Least One Dose Limiting Toxicity — 0; 0; 1 participants with DLTs
Phase 2 N=20 A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
Metastatic Colorectal Cancer
Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…
N/A N=52 Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy.
Colorectal Cancer
Primary: Complete Hepatic Response Rate at 3 Months — 79 percentage of participants
Phase 2 N=38 Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Metastatic Breast Cancer · Liver Metastases
Primary: Response Rate — 2; 13; 21; 1 Participants
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Phase 2 N=50 Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Liver Cancer · Metastatic Cancer
Primary: Time to Progression — 2.3; 7.2 Months
Phase 2 N=15 FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Colorectal Cancer
Primary: Overall Response Rate (ORR) — 75 percentage of evaluable participants
Phase 2 N=28 Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
Liver Cancer
Primary: Disease Response Rate — 12.5 percentage of participants with response
Phase 2 N=38 Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases
Rectal Cancer · Liver Metastases
Primary: Quality of Surgery for Primary Tumor — 2; 1; 15; 19 Participants — p=0.719
Phase 2 N=22 Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Liver Cancer
Primary: Median Overall Survival — 31.1 months
Phase 2 N=100 Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma
Hepatocellular Carcinoma · Metastasis · Invasion
Primary: Overall Survival — 333; 290 days — p=0.4593
Phase 2 N=19 Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Metastatic Carcinoma in the Liver · Recurrent Colorectal Carcinoma · Stage IV Colorectal Cancer AJCC v7
Primary: Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions — 7.25 fold change — p=0.046
N/A N=428 Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Progression Free Survival — 8.0; 7.2 Months — p=0.0013
Phase 3 N=483 Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
Liver Metastases · Colorectal Neoplasms · Neoplasm Metastasis
Primary: Overall Survival — 390; 405 Days
Phase 2 N=80 A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
Colorectal Cancer
Primary: Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor — 48.7; 61.0; 33.3; 51.2 percentage of participants — p=0.2707
Phase 2 N=73 Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
Colorectal Cancer · Metastatic Cancer
Primary: Recurrence-free Survival at 2 Years — 13; 10 participants
Phase 3 N=321 Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer
Colorectal Neoplasms · Liver Neoplasms
Primary: Disease Free Survival (DFS) — 21.6; 24.7 months — p=0.468
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Phase 2 N=32 Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
Colorectal Cancer · Liver Neoplasms
Primary: Incidence of Adverse Events and Dose Limiting Adverse Events — 0; 69; 47; 44 percentage of participants
Phase 2 N=51 Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Overall Survival — 175.0; 169.0 Days — p=0.0021
Phase 3 N=175 Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants